Both Y1 and Y5 receptor antagonists are being explored as a potential therapeutic strategy for obesity and related metabolic disorders by influencing satiety and energy balance, while the direct link between Y1/Y5 receptor antagonisms and leptin resistance is not fully elucidated (140). The gene discussed is LEP; the disease is metabolic disease.